Juvenile Idiopathic Arthritis

01Pathophysiology

Juvenile Idiopathic Arthritis is a group of chronic arthritides defined by the onset of arthritis before age 16 that persists for at least 6 weeks with no other identifiable cause. The disease results from a dysregulated immune response where autoreactive T cells and pro-inflammatory cytokines attack the synovial membrane. This triggers synovial hypertrophy and pannus formation, which is the same destructive tissue seen in adult rheumatoid arthritis.

The inflamed synovium produces excess synovial fluid, explaining the joint effusion and swelling seen on exam. Ongoing inflammation erodes cartilage and underlying bone over time, which accounts for the joint space narrowing and bony erosions visible on late-stage imaging. Morning stiffness occurs because inflammatory cytokines accumulate in the joint overnight during immobility; once the child begins moving, the fluid redistributes and stiffness improves. This pattern of "stiffness that gets better with activity" (also called a gelling phenomenon) is the hallmark that distinguishes inflammatory arthritis from mechanical joint disease.

In the systemic subtype, the pathophysiology is driven predominantly by the innate immune system rather than adaptive immunity. Macrophage activation leads to overproduction of IL-1 and IL-6, which cause the characteristic daily spiking (quotidian) fevers, hepatosplenomegaly, and serositis. This innate immune overdrive also explains why systemic JIA responds poorly to methotrexate (which targets adaptive immunity) and instead responds to IL-1 and IL-6 blockade. A feared complication of systemic JIA is macrophage activation syndrome (MAS), a life-threatening cytokine storm characterized by paradoxically falling ESR, skyrocketing ferritin, pancytopenia, and liver dysfunction.

In the oligoarticular subtype, chronic anterior chamber inflammation leads to uveitis, which is often asymptomatic ("white and quiet" eye). The mechanism involves autoreactive T cells targeting ocular antigens in the anterior uveal tract. Because the eye is not painful or red in most cases, uveitis can progress silently to synechiae, band keratopathy, and vision loss if slit-lamp screening is not performed.

02Classification and Clinical Manifestation

The international classification recognizes several subtypes, each with distinct demographics, joint patterns, and extra-articular features. Distinguishing subtypes is critical because management and prognosis differ.

The quotidian fever of systemic JIA is one of the most recognizable patterns on an exam vignette. The temperature spikes to 39 degrees Celsius or higher once or twice daily (classically in the late afternoon or evening) and then returns to normal or below normal between spikes. The salmon-colored rash is evanescent, meaning it appears during febrile episodes and fades when the fever resolves, often provoked by a warm bath (Koebner phenomenon).

03Diagnostic Workup

JIA is a clinical diagnosis. There is no single confirmatory lab test. The diagnosis requires arthritis in a patient younger than 16, lasting at least 6 weeks, with exclusion of other causes (infection, malignancy, connective tissue disease, reactive arthritis). The role of lab tests is to classify the subtype and screen for complications, not to confirm the diagnosis itself.

The best initial step when a child presents with chronic joint swelling is a thorough history and physical examination combined with basic inflammatory markers (ESR, CRP, CBC). ANA and RF are then ordered to classify the subtype and risk-stratify for uveitis.

When the presentation is acute monoarthritis (a single hot, swollen joint), the most critical first step is to rule out septic arthritis. Joint aspiration with Gram stain, culture, and cell count must be performed before attributing the findings to JIA. A septic joint is a surgical emergency and cannot be missed.

Slit-lamp examination is mandatory for all newly diagnosed JIA patients. The frequency of follow-up screening depends on the subtype, ANA status, and age at onset. ANA-positive children with oligoarticular JIA younger than 7 at onset are at the highest risk and require slit-lamp exams every 3 months. Uveitis in JIA is typically chronic, bilateral, and anterior. It is usually asymptomatic in oligoarticular and polyarticular subtypes (unlike the painful, red, acute uveitis seen in enthesitis-related arthritis).

MRI is the most sensitive imaging modality for detecting early synovitis, cartilage loss, and bone marrow edema before radiographic changes appear. It is not required for diagnosis but is used when clinical assessment is uncertain or to evaluate disease activity and damage in complex cases.

If systemic JIA is suspected and the child deteriorates with falling blood counts, falling ESR, rising ferritin, rising liver enzymes, and rising triglycerides, the diagnosis of MAS must be considered immediately. The hallmark laboratory triad of MAS is markedly elevated ferritin with paradoxically falling ESR and new cytopenias. A ferritin-to-ESR ratio that is disproportionately high should raise concern.

04Management and Treatment

Acute management begins with NSAIDs for symptom relief. For oligoarticular disease with one or two involved joints, intra-articular corticosteroid injection is often the most effective early intervention and may be sufficient as monotherapy for persistent oligoarticular JIA. Triamcinolone hexacetonide is preferred because it provides longer duration of remission compared to triamcinolone acetonide.

If the disease involves five or more joints, or if the oligoarticular subtype extends beyond four joints, methotrexate becomes the cornerstone of treatment. It is given once weekly, not daily. Folic acid supplementation reduces side effects (oral ulcers, nausea, hepatotoxicity) without diminishing efficacy. Methotrexate is teratogenic (Category X) and must be accompanied by strict contraception counseling in adolescent females. Baseline and periodic monitoring of liver enzymes, CBC, and renal function is required.

When methotrexate fails or is not tolerated, biologic therapy is added. For polyarticular subtypes, anti-TNF agents (etanercept or adalimumab) are the standard next step. Tuberculosis screening with a PPD or interferon-gamma release assay is mandatory before starting any anti-TNF agent, because TNF blockade can reactivate latent tuberculosis. For JIA-associated uveitis, adalimumab is preferred over etanercept; etanercept has been shown to be less effective in controlling ocular inflammation.

For systemic JIA, the treatment paradigm differs. Because the disease is driven by IL-1 and IL-6 rather than by adaptive immunity, methotrexate and anti-TNF agents are often ineffective. IL-1 inhibitors (anakinra or canakinumab) or IL-6 inhibitors (tocilizumab) are the targeted therapies of choice. Systemic corticosteroids are used for bridging in severe cases but should be tapered as soon as biologic therapy achieves disease control, given the adverse effects on growth and bone density in children.

MAS is treated as a medical emergency with high-dose intravenous methylprednisolone (30 mg/kg/day, max 1 g, for 3 consecutive days), followed by cyclosporine A if there is no rapid improvement. Anakinra at high doses has also shown benefit in refractory MAS. Early recognition and aggressive treatment are critical because MAS carries significant mortality.

05Differential Diagnosis and Distractors

The two most commonly tested distractors are septic arthritis (for acute presentations) and acute leukemia (for subacute presentations with systemic symptoms). Always consider malignancy when a child presents with bone or joint pain, especially if there is nocturnal pain, pancytopenia, or lymphadenopathy that seems disproportionate.

06Traps and High-Yield Pearls

The single most common trap with JIA questions involves uveitis screening. Students either forget that uveitis is frequently asymptomatic or fail to identify which patients need the most aggressive screening. The child will not complain of eye pain or redness in the oligoarticular and polyarticular subtypes. The vignette may describe a young ANA-positive girl with knee arthritis who has been doing well, followed by a question about the "most appropriate next step." The answer is slit-lamp examination, not more joint imaging or a change in arthritis therapy. Missing uveitis leads to permanent vision loss, and exam writers test whether you understand that screening must be proactive rather than symptom-driven.

A second common error is confusing the fever pattern in systemic JIA with that of an infectious process. The quotidian fever of systemic JIA spikes high and returns to baseline or below between episodes, which differs from the persistent or remittent fevers of sepsis or endocarditis. The salmon-colored rash that appears with fever and vanishes between episodes is the discriminating clue.

Third, students frequently miss MAS when a child with systemic JIA suddenly deteriorates. The trap is the falling ESR. In most inflammatory conditions, worsening disease means rising ESR. In MAS, the ESR drops because fibrinogen is consumed (and ESR depends on fibrinogen). A dropping ESR with a rising ferritin in a sick child with systemic JIA should immediately suggest MAS, not clinical improvement.

Finally, remember that the joint pattern matters for classification: migratory arthritis points to rheumatic fever, while additive arthritis (joints accumulate rather than move) points to JIA. When the vignette describes arthritis that "moves from one joint to another," think rheumatic fever. When it describes progressively more joints becoming involved over weeks, think JIA.

The core competency being tested in JIA questions is the ability to classify the subtype based on the clinical vignette (joint count, age, sex, lab profile), select the appropriate management tier (NSAIDs, intra-articular steroids, methotrexate, or biologics), and recognize the silent complications (uveitis, MAS) that require proactive screening and urgent intervention.